Using AI to predict light chain amyloidosis in patients with MGUS and SMM
10 Views
administrator
11/23/23
Eli Muchtar, MD, Mayo Clinic, Rochester, MN, comments on the potential of artificial intelligence (AI) in predicting the risk of developing AL amyloidosis in patients with multiple myeloma precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
-
Category
Show more
Facebook Comments
No comments found